PSCA|CAR T cell therapy in metastatic castration|resistant prostate ...

PSCA-CAR T cell therapy in metastatic castration-resistant prostate ...

Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains lethal. Chimeric antigen receptor (CAR) ...

Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T ...

Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC). Authors: Tanya B ...

Final results from phase I study of PSCA-targeted chimeric antigen ...

Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant ...

Study: CAR T for Prostate Cancer Shows Efficacy | City of Hope

The trial used CAR T cell therapy to treat 14 prostate stem cell antigen (PSCA)-positive patients who had metastatic castration resistant ...

PSCA CAR T Cells Induce Therapeutic Responses in Metastatic ...

Immunotherapies such as immune checkpoint inhibitors or vaccines have generally been ineffective in metastatic castration-resistant prostate ...

Final Results from Phase I Study of PSCA-Targeted CAR T Cells in ...

... metastatic castration resistant prostate cancer (mCRPC), phase I study of PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in mCRPC.

PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the ...

... Treatment of Patients with PSCA+ Metastatic Castration-Resistant Prostate Cancer. ... Castration-resistant prostate cancer continues to grow and spread ...

Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate ...

PSCA-CAR T Cells in Treating Patients with PSCA+ Metastatic Castration Resistant Prostate Cancer. [(accessed on 2 January 2022)]; Available ...

PSCA-Targeted CAR T-Cell Therapy Demonstrates Safety ... - OncLive

The use of prostate stem cell antigen–targeted CAR T-cell therapy ... T cells in patients with metastatic castration resistant prostate cancer ( ...

CAR T-Cell Therapy Demonstrates Promising Results for mCRPC

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med. 2024;30:1636-1644. doi:10.1038/s41591 ...

Genetically Engineered Cells (PSCA ɣδ-Enriched CAR T-cells) for ...

Genetically Engineered Cells (PSCA ɣδ-Enriched CAR T-cells) for the Treatment of Castration Resistant Prostate Cancer Metastatic in the Bone.

PSCA-CAR T cell therapy in metastatic castration-resistant prostate ...

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial · Abstract. Despite recent therapeutic advances, ...

City of Hope CAR T cell therapy for advanced prostate cancer ...

The trial treated 14 prostate stem cell antigen (PSCA)-positive patients who had metastatic castration resistant prostate cancer (mCRPC) ...

CAR-T cell therapy: a potential new strategy against prostate cancer

Although it is often a manageable tumor, around 20% of patients develop metastases and the disease eventually evolves into metastatic castration-resistant PCa ( ...

CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate ...

CAR T-Cell Use Possible in Metastatic Castration-Resistant Prostate Cancer · FDA Lifts Clinical Holds Placed on 3 CAR T-cell Therapy Trials.

Improving immunotherapy for advanced prostate cancer

A dose of CAR T cells delayed tumor progression and extended survival to 97 days. In a separate model of metastatic castration-resistant ...

γδ-Enriched CAR-T cell therapy for bone metastatic castrate ...

Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC).

Trial of CAR-T for prostate cancer takes steps toward 'potentially ...

... developed at City of Hope to treat 14 men with metastatic castration-resistant prostate cancer and prostate stem-cell antigen (PSCA) expression.

Left out in the cold: Moving beyond hormonal therapy for the ...

Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol ...

PSCA-CAR T Cell Therapy in Metastatic Castration-Resistant ...

Metastatic castration-resistant prostate cancer (mCRPC) remains lethal despite treatment advances. Notably, resistance to immunotherapy is ...